These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 426001)
1. Predictive value of in vitro colony and cluster formation in acute nonlymphocytic leukemia. Goldberg J; Tice D; Nelson DA; Gottlieb AJ Am J Med Sci; 1979; 277(1):81-4. PubMed ID: 426001 [TBL] [Abstract][Full Text] [Related]
2. Predictive value of the CFU-C assay in acute nonlymphocytic leukemia. Kirshner JJ; Goldberg J; Nelson DA; Gottlieb AJ Am J Med; 1982 Apr; 72(4):615-19. PubMed ID: 7041644 [TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for adult acute nonlymphocytic leukemia with daunorubicin and cytosine arabinoside. Cassileth PA; Katz ME Cancer Treat Rep; 1977 Nov; 61(8):1441-5. PubMed ID: 922749 [TBL] [Abstract][Full Text] [Related]
4. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Wolff SN; Marion J; Stein RS; Flexner JM; Lazarus HM; Spitzer TR; Phillips GL; Herzig RH; Herzig GP Blood; 1985 Jun; 65(6):1407-11. PubMed ID: 3995177 [TBL] [Abstract][Full Text] [Related]
5. Treatment of acute nonlymphocytic leukemia in elderly patients: a prospective study of intensive chemotherapy. Peterson BA; Bloomfield CD Cancer; 1977 Aug; 40(2):647-52. PubMed ID: 890652 [TBL] [Abstract][Full Text] [Related]
6. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Yates JW; Wallace HJ; Ellison RR; Holland JF Cancer Chemother Rep; 1973; 57(4):485-8. PubMed ID: 4586956 [No Abstract] [Full Text] [Related]
7. Assessment of the drug sensitivity of acute nonlymphocytic leukaemia using the in vitro clonogenic assay. Preisler HD; Azarnia N Br J Haematol; 1984 Dec; 58(4):633-40. PubMed ID: 6518136 [TBL] [Abstract][Full Text] [Related]
8. An attempt at synchronization of marrow cells in acute leukemia: relationship to therapeutic response. Kremer WB; Vogler WR; Chan YK Cancer; 1976 Jan; 37(1):390-403. PubMed ID: 1082365 [TBL] [Abstract][Full Text] [Related]
9. Monitoring the remission induction therapy of acute nonlymphoblastic leukemia by bone marrow cell culture criteria. Bohinjec J; Zontar D; Kralj J Leuk Res; 1985; 9(3):369-73. PubMed ID: 3999798 [TBL] [Abstract][Full Text] [Related]
10. Therapy in childhood acute nonlymphocytic leukemia (ANLL). Evolution of current concepts of chemotherapy. Steuber CP Am J Pediatr Hematol Oncol; 1981; 3(4):379-88. PubMed ID: 6174052 [TBL] [Abstract][Full Text] [Related]
11. Randomized clinical comparison of daunorubicin (NSC-82151) alone with a combination of daunorubicin, cytosine arabinoside (NSC-63878), 6-thioguanine (NSC-752), and pyrimethamine (NSC-3061) for the treatment of acute nonlymphocytic leukemia. Wiernik PH; Schimpff SC; Schiffer CA; Lichtenfeld JL; Aisner J; O'Connell MJ; Fortner C Cancer Treat Rep; 1976 Jan; 60(1):41-53. PubMed ID: 1069608 [TBL] [Abstract][Full Text] [Related]
12. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update. Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687 [TBL] [Abstract][Full Text] [Related]
13. Intensified remission induction therapy for acute nonlymphocytic leukemia (ANLL). Treatment report on 60 patients. Urbanitz D; Büchner T; Kamanabroo D; Hiddemann W; Schulte H; van de Loo J Blut; 1981 Aug; 43(2):129-33. PubMed ID: 7260406 [TBL] [Abstract][Full Text] [Related]
15. Response to treatment in acute non-lymphatic leukaemia: prognostic value of colony forming and colony stimulating capacities of bone marrow and blood cells compared to other parameters. Beran M; Reizenstein P; Uden AM Br J Haematol; 1980 Jan; 44(1):39-50. PubMed ID: 6966502 [TBL] [Abstract][Full Text] [Related]
16. Serial studies on in vitro colony formation in patients with acute leukemia in relation to the maintenance of remission. Kubota K; Mizoguchi H; Miura Y; Muto Y; Chiyoda S; Takaku F Am J Hematol; 1978; 5(4):285-90. PubMed ID: 288309 [TBL] [Abstract][Full Text] [Related]
17. Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Preisler HD; Rustum Y; Henderson ES; Bjornsson S; Creaven PJ; Higby DJ; Freeman A; Gailani S; Naeher C Blood; 1979 Mar; 53(3):455-64. PubMed ID: 760861 [TBL] [Abstract][Full Text] [Related]
18. Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). I. Response and toxicity in four different regimens. Büchner T; Urbanitz D; Hiddemann W; Kamanabroo D; Meister R; Balleisen L; Delvos U; Lagrèze EM; Schmitz-Huebner U; Schulte H; van de Loo J Blut; 1979 Aug; 39(2):133-40. PubMed ID: 476310 [No Abstract] [Full Text] [Related]
19. Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria. Curtis JE; Cowan DH; Bergsagel DE; Hasselback R; McCulloch EA Can Med Assoc J; 1975 Aug; 113(4):289-94. PubMed ID: 1056807 [TBL] [Abstract][Full Text] [Related]